-
Featured
Gene Profiling of Bladder Tumors Shows Promise for Identifying Candidates for Trimodality Therapy
Research by Massachusetts General Hospital Cancer Center oncologists suggests gene profiling of tumors from patients with muscle-invasive bladder cancer can guide rational selection of those who will benefit most from bladder-preserving trimodality therapy.
-
Researching Radiation Therapy for Transgender Cancer Patients
A Mass General Cancer Center radiation oncologist published a unique review of considerations in radiation for patients with cancer who have had gender-affirming surgery.
-
New Research Supports Trimodality Therapy for Bladder Cancer
A new Massachusetts General Hospital study compares bladder cancer treatment options and strongly supports bladder preservation with trimodality therapy.
-
Novel AI Model Predicts Risk of Hepatic Toxicity After Radiation Therapy for HCC
Mass General Cancer Center researchers have created a new machine learning approach to predict an individual patient's risk of hepatic toxicity after conformal radiation therapy for hepatocellular carcinoma: training convolutional neural networks on differential dose-volume histograms as well as clinical factors.
-
Auto-Contouring Model Performs Well for Prostate Cancer Patients Who Receive Radiopaque Hydrogel Spacer
Yi Wang, PhD, Jason A. Efstathiou, MD, DPhil, and colleagues have validated a CT-based deep learning model that provides automated contouring when planning radiation therapy for prostate cancer patients who receive the SpaceOAR Vue rectal spacer.
-
Radiation Oncology Department Announces First-Ever Director of DE&I: Q&A with Sophia Kamran, MD
Sophia Kamran, MD, first-ever Diversity, Equity, and Inclusion (DE&I) director for Mass General Cancer Center's Radiation Oncology department, shares more about her work in this space.
Mass General Cancer Center Contributors
-
David T. Miyamoto, MD, PhD
Attending Radiation Oncologist, Department of Radiation Oncology, Massachusetts General Hospital, Investigator, Center for Cancer Research, Mass General Cancer Center, Assistant Professor of Radiation Oncology, Harvard Medical School
Recent Article
High MRE11 in Muscle-invasive Bladder Tumors Linked to Better Survival After Chemoradiation -
Jason A. Efstathiou, MD, DPhil
Vice-Chair, Faculty & Academic Affairs, Director, Genitourinary Division, Department of Radiation Oncology, Massachusetts General Hospital, Co-Director, The Claire and John Bertucci Center for Genitourinary Cancers, Mass General Cancer Center, Professor of Radiation Oncology, Harvard Medical School
Recent Article
Less Aggressive Protocol Suitable for Muscle-invasive Bladder Cancer in Noncystectomy Candidates -
Theodore Sunki Hong, MD
Director, Gastrointestinal Service, Department of Radiation Oncology, Co-Director, Tucker Gosnell Center for Gastrointestinal Cancers, Mass General Cancer Center, Professor of Radiation Oncology, Harvard Medical School
Recent Article
Novel AI Model Predicts Risk of Hepatic Toxicity After Radiation Therapy for HCC
-
William Shipley, MD
Andres Soriano Distinguished Professor of Radiation Oncology, Harvard Medical School
Recent Article
Alternative Chemoradiation Regimen of Trimodal Therapy Found Effective for Muscle-invasive Bladder Cancer
Mass General Department of Radiation Oncology
The Department of Radiation Oncology combines clinical expertise, compassionate care, and advanced radiation therapies to deliver the safest, most effective treatments for cancer and benign tumors.
